Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

14 Jan 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Acute Respiratory Distress Syndrome · Phase 2 · Enrollment 600 · Sponsor: BioAegis Therapeutics Inc.

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Infectious Disease on 14 Jan 2026. The item focuses on Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS). Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT05947955

Open Original Source More Feed Items

Related by Condition/Drug

Nat ImmunolRelated by Specialty

A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines

Infectious Disease • 22 May 2026

Front ImmunolRelated by Specialty

Development of an improved preclinical humanized mouse platform representing the diverse clinical phenotypes of Sjögren’s syndrome

Infectious Disease • 22 May 2026

Front ImmunolRelated by Specialty

Integrative multi-omics analysis reveals inflammation-related molecular networks in acute mountain sickness

Infectious Disease • 22 May 2026

Nat ImmunolRelated by Specialty

Mapping where mouse models match — and miss — human tumor immunity

Infectious Disease • 21 May 2026

Feed Metadata

Source

ClinicalTrials.gov